Abstract
A central obstacle to the design of a global HIV vaccine is viral diversity. Antigenic differences in envelope proteins result in distinct HIV serotypes, operationally defined such that antibodies raised against envelope molecules from one serotype will not bind envelope molecules from a different serotype. The existence of serotypes has presented a similar challenge to vaccine development against other pathogens. In such cases, antigenic diversity has been addressed by vaccine design. For example, the poliovirus vaccine includes three serotypes of poliovirus, and Pneumovax(ρ) presents a cocktail of 23 pneumococcal variants to the immune system. It is likely that a successful vaccine for HIV must also comprise a cocktail of antigens. Here, data relevant to the development of cocktail vaccines, designed to harness diverse, envelope-specific Bcell and T-cell responses, are reviewed.
Keywords: hiv envelope protein, cocktail, breadth
Current HIV Research
Title: HIV Vaccine Rationale, Design and Testing
Volume: 3 Issue: 2
Author(s): Robert E. Sealy, Julia L. Hurwitz, Louis N. Martin, James L. Blanchard, Peter C. Doherty, Pamela J. Freiden, Timothy D. Lockey, Brita Brown, John Stambas, Karen S. Slobod, Bart G. Jones, Amy Zirkel, Sherri Surman, Xiaoyan Zhan, Scott A. Brown, Mattia Bonsignori and Chris Coleclough
Affiliation:
Keywords: hiv envelope protein, cocktail, breadth
Abstract: A central obstacle to the design of a global HIV vaccine is viral diversity. Antigenic differences in envelope proteins result in distinct HIV serotypes, operationally defined such that antibodies raised against envelope molecules from one serotype will not bind envelope molecules from a different serotype. The existence of serotypes has presented a similar challenge to vaccine development against other pathogens. In such cases, antigenic diversity has been addressed by vaccine design. For example, the poliovirus vaccine includes three serotypes of poliovirus, and Pneumovax(ρ) presents a cocktail of 23 pneumococcal variants to the immune system. It is likely that a successful vaccine for HIV must also comprise a cocktail of antigens. Here, data relevant to the development of cocktail vaccines, designed to harness diverse, envelope-specific Bcell and T-cell responses, are reviewed.
Export Options
About this article
Cite this article as:
Sealy E. Robert, L. Hurwitz Julia, N. Martin Louis, L. Blanchard James, C. Doherty Peter, J. Freiden Pamela, D. Lockey Timothy, Brown Brita, Stambas John, Slobod S. Karen, Jones G. Bart, Zirkel Amy, Surman Sherri, Zhan Xiaoyan, Brown A. Scott, Bonsignori Mattia and Coleclough Chris, HIV Vaccine Rationale, Design and Testing, Current HIV Research 2005; 3 (2) . https://dx.doi.org/10.2174/1570162053506928
DOI https://dx.doi.org/10.2174/1570162053506928 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pulmonary Embolism and Pregnancy
Current Women`s Health Reviews Mucoadhesive Chitosan Derivatives as Novel Drug Carriers
Current Pharmaceutical Design Non-coding RNAs in Exosomes: New Players in Cancer Biology
Current Genomics SUI-Current Medicinal Therapeutic Options
Current Women`s Health Reviews Implication of Nanofibers in Oral Drug Delivery
Current Pharmaceutical Design Structural Insights into Substrate Binding of Brown Spider Venom Class II Phospholipases D
Current Protein & Peptide Science Drug Delivery Systems with Modified Release for Systemic and Biophase Bioavailability
Current Clinical Pharmacology Local Physiological Regulation and Modern Treatments in Gynaecology
Current Women`s Health Reviews Is the Cytoskeleton an Intracellular Receptor for Adrenomedullin and PAMP?
Current Protein & Peptide Science Epidemiology, Clinical Presentation and Treatment of Mucosal Melanoma
Clinical Cancer Drugs Thermodynamic and Kinetic Aspects Involved in the Development of Nanocarriers and Drug Delivery Systems Based on Cationic Biopolymers
Current Pharmaceutical Design Genistein: A Phytoestrogen with Multifaceted Therapeutic Properties
Mini-Reviews in Medicinal Chemistry Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now?
Current Vascular Pharmacology Functional Food: Product Development and Health Benefits
Recent Patents on Engineering Understanding the Molecular Properties and Metabolism of Top Prescribed Drugs
Current Topics in Medicinal Chemistry New Treatments for Emerging Cystic Fibrosis Pathogens other than Pseudomonas
Current Pharmaceutical Design Update on Laser Photochemotherapy: An Alternative for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Development of HIV Reservoir Targeted Long Acting Nanoformulated Antiretroviral Therapies
Current Medicinal Chemistry Formulation, Characterization and In vitro Cytotoxicity of 5-Fluorouracil Loaded Polymeric Electrospun Nanofibers for the Treatment of Skin Cancer
Recent Patents on Nanotechnology Protein-Based HIV-1 Microbicides
Current HIV Research